CELC Earnings Prediction
The chart below shows how CELC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CELC sees a +1.33% change in stock price 10 days leading up to the earnings, and a +4.08% change 10 days following the report. On the earnings day itself, the stock moves by +1.03%. This data can give you a slight idea of what to expect for the next quarter's release.
CELC Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.70
-15.66%
12.90%
No Data Available
CELC Earnings Analysis
Celcuity Inc. Common Stock Corporation (CELC.O) Earnings Conference Call
Positive
Cohort Enrollment Milestone: The PIK3CA wild-type cohort is 100% enrolled, an important milestone reflecting excellent execution by our clinical development and operations teams.
Cohort Enrollment Progress: Enrollment in the PIK3CA mutant cohort is on plan.
Study Participation Interest: We are very pleased with the interest we are receiving from our current VIKTORIA-1 sites as well as new sites that have expressed interest in participating in this study.
Patient Enrollment Timeline: We expect these activities will allow us to enroll our first patient in the second quarter of 2025.
Regulatory Work Progress: We are on track to conducting the regulatory work that's required outside the US so that we can get those sites activated and begin screening patients.
Negative
Quarterly Net Loss Comparison: Our third quarter net loss was $29.8 million or $0.70 per share compared to $18.4 million net loss or $0.83 per share for the third quarter of 2023.
Adjusted Net Loss Comparison: Our non-GAAP adjusted net loss was $27.6 million or $0.65 per share for the third quarter of 2024 compared to non-GAAP adjusted net loss of $17.3 million or $0.78 per share for the third quarter of 2023.
R&D Expense Increase: Research and development expenses were $27.6 million for the third quarter of 2024 compared to $17.5 million for the third quarter of 2023.
Administrative Expense Increase: General and administrative expenses were $2.5 million for the third quarter of 2024, and compared to $1.4 million for the third quarter of 2023.
Operating Cash Flow Comparison: Net cash used in operating activities for the third quarter of 2024 was $20.6 million compared to $12.7 million for the third quarter of 2023.
CELC FAQs
How does CELC typically perform around its earnings report dates?
Is Celcuity Inc. (CELC) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CELC Earning Call Sentiment
Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CELC.O
2.31%Positive
The earnings call reveals financial challenges with increased net loss and high R&D expenses, indicating financial strain. While there is optimism about future trials and market potential, the lack of a share repurchase program and competitive and regulatory risks overshadow positive aspects. The Q&A highlights uncertainties in clinical development and competition, with management's vague responses adding to concerns. Overall, these factors suggest a negative sentiment towards the stock price in the short term.